Lipo C vs MOTS-c: A Research Reference
Two compounds, two separate research records. This reference sets Lipo C and MOTS-c against each other on parameters a laboratory can independently verify.
Compound profiles
Lipo C in the indexed record
Indexed output for Lipo C stands at 19 records, a limited literature, alongside 27 registered studies on ClinicalTrials.gov.
Recent indexed work appears in Eur J Pharm Sci, Nature, PLoS One, spanning 2005–2025.
- Island-wide characterization of agricultural production challenges the demographic collapse hypothesis for Rapa Nui (Easter Island) — Sci Adv, 2024. PMID: 38905341
- Inhibitory effects and gene expression analysis of chemotherapeutic photodynamic therapy by using a liposomally formulated indocyanine green derivative — Photodiagnosis Photodyn Ther, 2022. PMID: 35700912
- Targeting liposomes with protein drugs to the blood-brain barrier in vitro — Eur J Pharm Sci, 2005. PMID: 15911226
- Walking statues: Easter Island’s complex history — Nature, 2011. PMID: 22051666
MOTS-c in the indexed record
Indexed output for MOTS-c stands at 255 records, a moderate literature, alongside 9 registered studies on ClinicalTrials.gov.
Publications carrying this compound include Adv Sci (Weinh), Cardiovasc Drugs Ther, Front Endocrinol (Lausanne), spanning 2022–2025.
- Mitochondrial-Derived Peptide MOTS-c Suppresses Ovarian Cancer Progression by Attenuating USP7-Mediated LARS1 Deubiquitination — Adv Sci (Weinh), 2024. PMID: 39321430
- MOTS-c attenuates lung ischemia-reperfusion injury via MYH9-Dependent nuclear translocation and transcriptional activation of antioxidant genes — Redox Biol, 2025. PMID: 40403491
- MOTS-c: Magical Molecule for Diabetic Cardiomyopathy? — Cardiovasc Drugs Ther, 2025. PMID: 40172798
- MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation — Front Endocrinol (Lausanne), 2023. PMID: 36761202
Classification and why it matters
Lipo C and MOTS-c sit in different structural classes, and that classification is what determines whether a published protocol for one has any bearing on the other. Peptide research compounds are grouped by sequence length, origin and the receptor families the literature associates with them — not by the outcome a reader might be looking for.
Reading across classes is the most common error in a literature review. A protocol developed for Lipo C describes conditions validated for Lipo C: concentration ranges, solvent choice, incubation windows and control selection were all established against that compound. Applying those same conditions to MOTS-c without re-validation produces data that cannot be compared back to the source publication.
Where the two compounds are studied in overlapping models, the published work almost always treats them as separate arms rather than as substitutes. That separation is the useful signal: it indicates the research record does not consider them equivalent.
Side-by-side research profile
| Parameter | Lipo C | MOTS-c |
|---|---|---|
| PubMed indexed records | 19 | 255 |
| Registered studies (ClinicalTrials.gov) | 27 | 9 |
| Literature depth | Emerging | Moderate |
| Handling class | Lyophilised powder | Lyophilised powder |
| Designation | Research use only | Research use only |
How the literature differs
The indexed record is not symmetrical between these two compounds. MOTS-c carries 236 more indexed records than Lipo C, which means published methodology, characterisation data and replication attempts are more readily located for MOTS-c. For a researcher planning a literature review, that asymmetry usually determines which compound has established reference protocols and which requires primary-source work.
Registered study counts (27 vs 9) track a different signal — formal study registration rather than published output — and the two figures frequently diverge.
Verification and documentation
What is in the vial is established by lot-specific analytics, not by label text. HPLC gives purity as a share of total peak area; mass spectrometry confirms the molecular weight matches the intended sequence. Neither substitutes for the other.
Storage and stability
Lyophilised peptide is the stable form. Held sealed at -20°C and shielded from light, it tolerates long storage; once reconstituted that tolerance drops sharply and the working solution is treated as short-lived.
Each freeze-thaw cycle costs integrity, which is why reconstituted material is normally split into single-use aliquots.
Frequently asked questions
Are Lipo C and MOTS-c the same compound?
No. They are structurally distinct research compounds with separate literature records — 19 indexed records for Lipo C and 255 for MOTS-c.
How should these compounds be stored?
Lyophilised material is conventionally stored at -20°C protected from light. Reconstituted solution is far less stable and is held at 2-8°C for short-duration laboratory work only.
What is the regulatory status of these compounds?
Neither is an approved drug. Both are supplied strictly for in-vitro laboratory research and are not intended for human or veterinary consumption.
Which of Lipo C or MOTS-c has more published research?
MOTS-c, with 255 indexed PubMed records against 19.
Related references
- MOTS-c — product and lot documentation
- Certificate of analysis & purity testing
- Research reference index
Research use only. The compounds discussed are supplied for in-vitro laboratory research. They are not drugs, are not approved for the diagnosis, treatment, cure or prevention of any condition, and are not intended for human or veterinary consumption.